Synthesis and antitumor activities of novel rhein α-aminophosphonates conjugates
- 1 January 2014
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (2) , 501-507
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803European Journal of Cancer, 2011
- A Novel Water-Soluble Gossypol Derivative Increases Chemotherapeutic Sensitivity and Promotes Growth Inhibition in Colon CancerJournal of Medicinal Chemistry, 2010
- A review on oxaliplatin-induced peripheral nerve damageCancer Treatment Reviews, 2008
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Design of targeting ligands in medicinal inorganic chemistryChemical Society Reviews, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Antibody targeted drugs as cancer therapeuticsNature Reviews Drug Discovery, 2006
- Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicityCoordination Chemistry Reviews, 2005
- A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patientsBritish Journal of Cancer, 2005
- The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines, UFT/Leucovorin (ORZEL and S-1: a Review of Their Clinical Development and Therapeutic PotentialInvestigational New Drugs, 2000